Medacta Group SA
SIX:MOVE

Watchlist Manager
Medacta Group SA Logo
Medacta Group SA
SIX:MOVE
Watchlist
Price: 110.8 CHF 2.21% Market Closed
Market Cap: 2.2B CHF
Have any thoughts about
Medacta Group SA?
Write Note

Intrinsic Value

The intrinsic value of one MOVE stock under the Base Case scenario is 120.15 CHF. Compared to the current market price of 110.8 CHF, Medacta Group SA is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MOVE Intrinsic Value
120.15 CHF
Undervaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medacta Group SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MOVE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MOVE?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Medacta Group SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Medacta Group SA

Provide an overview of the primary business activities
of Medacta Group SA.

What unique competitive advantages
does Medacta Group SA hold over its rivals?

What risks and challenges
does Medacta Group SA face in the near future?

Has there been any significant insider trading activity
in Medacta Group SA recently?

Summarize the latest earnings call
of Medacta Group SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medacta Group SA.

Provide P/S
for Medacta Group SA.

Provide P/E
for Medacta Group SA.

Provide P/OCF
for Medacta Group SA.

Provide P/FCFE
for Medacta Group SA.

Provide P/B
for Medacta Group SA.

Provide EV/S
for Medacta Group SA.

Provide EV/GP
for Medacta Group SA.

Provide EV/EBITDA
for Medacta Group SA.

Provide EV/EBIT
for Medacta Group SA.

Provide EV/OCF
for Medacta Group SA.

Provide EV/FCFF
for Medacta Group SA.

Provide EV/IC
for Medacta Group SA.

Show me price targets
for Medacta Group SA made by professional analysts.

What are the Revenue projections
for Medacta Group SA?

How accurate were the past Revenue estimates
for Medacta Group SA?

What are the Net Income projections
for Medacta Group SA?

How accurate were the past Net Income estimates
for Medacta Group SA?

What are the EPS projections
for Medacta Group SA?

How accurate were the past EPS estimates
for Medacta Group SA?

What are the EBIT projections
for Medacta Group SA?

How accurate were the past EBIT estimates
for Medacta Group SA?

Compare the revenue forecasts
for Medacta Group SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medacta Group SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medacta Group SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medacta Group SA compared to its peers.

Compare the P/E ratios
of Medacta Group SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Medacta Group SA with its peers.

Analyze the financial leverage
of Medacta Group SA compared to its main competitors.

Show all profitability ratios
for Medacta Group SA.

Provide ROE
for Medacta Group SA.

Provide ROA
for Medacta Group SA.

Provide ROIC
for Medacta Group SA.

Provide ROCE
for Medacta Group SA.

Provide Gross Margin
for Medacta Group SA.

Provide Operating Margin
for Medacta Group SA.

Provide Net Margin
for Medacta Group SA.

Provide FCF Margin
for Medacta Group SA.

Show all solvency ratios
for Medacta Group SA.

Provide D/E Ratio
for Medacta Group SA.

Provide D/A Ratio
for Medacta Group SA.

Provide Interest Coverage Ratio
for Medacta Group SA.

Provide Altman Z-Score Ratio
for Medacta Group SA.

Provide Quick Ratio
for Medacta Group SA.

Provide Current Ratio
for Medacta Group SA.

Provide Cash Ratio
for Medacta Group SA.

What is the historical Revenue growth
over the last 5 years for Medacta Group SA?

What is the historical Net Income growth
over the last 5 years for Medacta Group SA?

What is the current Free Cash Flow
of Medacta Group SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medacta Group SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medacta Group SA

Current Assets 364.3m
Cash & Short-Term Investments 21.7m
Receivables 118.4m
Other Current Assets 224.2m
Non-Current Assets 367.5m
Long-Term Investments 892k
PP&E 291.7m
Intangibles 49.7m
Other Non-Current Assets 25.2m
Current Liabilities 165.8m
Accounts Payable 44.1m
Accrued Liabilities 32.3m
Other Current Liabilities 89.4m
Non-Current Liabilities 221.9m
Long-Term Debt 160.3m
Other Non-Current Liabilities 61.6m
Efficiency

Earnings Waterfall
Medacta Group SA

Revenue
544.3m EUR
Cost of Revenue
-174.6m EUR
Gross Profit
369.7m EUR
Operating Expenses
-291.8m EUR
Operating Income
78m EUR
Other Expenses
-21.8m EUR
Net Income
56.2m EUR

Free Cash Flow Analysis
Medacta Group SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Medacta Group's H1 2023 showcased a robust performance with top-line growth of over 21% in constant currency, reaching EUR 255 million in revenue. Adjusted EBITDA margin improved to 28.2%, even in the face of currency headwinds. The company experienced strong regional growth across Europe, North America, and the Asia Pacific, particularly in core product lines like hip and knee replacements, as well as robust growth in extremities and spine with an overall CAGR of over 15.5% since 2019. The gross profit margin stood at 68.9%, despite foreign exchange impacts. Adjusted EBIT increased by roughly 30% year-over-year to EUR 43.8 million, and profit for the period was EUR 29.1 million. Total debt remained below 1x EBITDA at EUR 127.9 million. No price cuts are expected in Australia for the second half of the year, and margin guidance suggests the first half is historically more profitable than the second.

What is Earnings Call?
Fundamental Scores

MOVE Profitability Score
Profitability Due Diligence

Medacta Group SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
58/100
Profitability
Score

Medacta Group SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

MOVE Solvency Score
Solvency Due Diligence

Medacta Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Low D/E
Short-Term Solvency
67/100
Solvency
Score

Medacta Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOVE Price Targets Summary
Medacta Group SA

Wall Street analysts forecast MOVE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOVE is 144.16 CHF with a low forecast of 135.34 CHF and a high forecast of 157.5 CHF.

Lowest
Price Target
135.34 CHF
22% Upside
Average
Price Target
144.16 CHF
30% Upside
Highest
Price Target
157.5 CHF
42% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MOVE?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for MOVE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MOVE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Medacta Group SA Logo
Medacta Group SA

Country

Switzerland

Industry

Health Care

Market Cap

2.2B CHF

Dividend Yield

0.5%

Description

Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The company is headquartered in Castel San Pietro, Ticino and currently employs 1,341 full-time employees. The company went IPO on 2019-04-04. The firm develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The firm designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.

Contact

TICINO
Castel San Pietro
Strada Regina 34

IPO

2019-04-04

Employees

1 341

Officers

Founder & Non Executive Chairman
Dr. Alberto Siccardi
Chief Executive Officer
Dr. Francesco Siccardi
Chief Financial Officer
Mr. Corrado Farsetta
Senior Director of Global Marketing
Gianluca Olgiati
Chief People Officer
Mr. Asif Hussain
Chief Supply Chain Officer
Mr. Alessandro Siccardi
Show More
Head of IT
Filippo Cappelli
Chief Commercial Officer
Mr. Giovanni Niccolo Galli
Chief Innovation Officer
Mr. Massimiliano Bernardoni
Secretary of the Board
Donato Cortesi
Show Less

See Also

Discover More
What is the Intrinsic Value of one MOVE stock?

The intrinsic value of one MOVE stock under the Base Case scenario is 120.15 CHF.

Is MOVE stock undervalued or overvalued?

Compared to the current market price of 110.8 CHF, Medacta Group SA is Undervalued by 8%.

Back to Top